BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Fox Business Segment Regarding Telehealth and the Future

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, was featured in a Fox Business segment on Friday titled, “Is telehealth the future of health care?” Dariohealth CEO Erez Raphael joined Fox’s Liz Claman to explain where he sees digital health and digital therapeutics going from here. “In order to treat chronic conditions, it’s very, very important to surround the user 24/7, and digital solutions and digital therapeutic solutions, such as Livongo, is a solution for chronic condition management,” Raphael stated, referring to Livongo Health Inc.’s (NASDAQ: LVGO) solution in a recent collaboration with Teladoc Health Inc. (NYSE: TDOC). “I think that this is the first of many transactions and mergers that we’re going to see in the space of digital health and digital therapeutics.”

To view the full news segment, visit http://ibn.fm/jlxtD

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, DarioHealth empowers individuals to make adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category 

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category…

2 days ago

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors

Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201,…

2 days ago

BioMedNewsBreaks – ProPhase Labs Inc. (NASDAQ: PRPH) Closes $23.6M Sale to Focus on Core Businesses

ProPhase (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, earlier this year announced the…

3 days ago

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction 

Bluejay (NASDAQ: BJDX) is a medical technology company developing rapid diagnostics on its Symphony platform…

4 days ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Military Contract Extension for Iridium PTT Services

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced that its subsidiary, Global Telesat Communications…

4 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to…

5 days ago